Press Releases

Filters (2)
May 21, 2019

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Read more
June 7, 2016

Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer

Read more
June 2, 2016

FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer

Read more
December 8, 2015

EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer

Read more
November 3, 2015

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…

Read more
April 16, 2015

Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference

Read more
November 18, 2014

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

Read more
May 28, 2014

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

Read more
June 4, 2013

Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies

Read more